Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bioxyne Limited ( (AU:BXN) ) has issued an announcement.
Bioxyne Limited has applied to the ASX for quotation of 30 million new fully paid ordinary shares, issued on 23 December 2025. The shares have been issued under an employee incentive scheme, signalling the company’s use of equity-based remuneration to align staff interests with shareholders and potentially broaden its free float, subject to market reception once the securities commence trading.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
More about Bioxyne Limited
Average Trading Volume: 2,263,434
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$92.21M
Learn more about BXN stock on TipRanks’ Stock Analysis page.